Online inquiry

IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9162MR)

This product GTTS-WQ9162MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9162MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15859MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ6407MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ645MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ8004MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ9114MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ9315MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ9849MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ5238MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW